Novavax Inc Covid-19 Vaccine
- All
- News
-
Novavax's Covid Vaccine Gets Emergency Use Nod For Kids Aged 12-17 In India
Novavax Inc said on Tuesday its COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years.
-
Japan Approves Moderna Covid Booster Shots Aiming To Increase Coverage
Japan on Thursday officially approved Moderna Inc's COVID-19 vaccine for its booster programme, while Novavax Inc filed for first approval of its shot in the country.
-
Novavax Covid Vaccine Gets First Authorization, "More Expected" Says CEO
Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within "weeks," its CEO said after the shot received its first emergency use authorization (EUA) from Indonesia.
-
Novavax-Serum Institute Vaccine Gets Emergency Use Approval In Indonesia
Biotechnology firm Novavax Inc and its partner Serum Institute of India on Monday said they have received the first emergency use authorisation (EUA) for Novavax''s COVID-19 vaccine, in Indonesia.
-
Serum Institute Seeks India Trial Of A Second Covid Vaccine
The Serum Institute of India, the world's biggest vaccine makers, has sought the drug regulator's permission to conduct a small domestic trial of the Novavax Inc COVID-19 vaccine that was found to be 89.3% effective in a UK trial, its CEO told Reuters on Friday.
-
Novavax Delays US Trial Of COVID-19 Vaccine Candidate To November
Novavax Inc on Tuesday delayed the start of a late-stage US trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.
-
Novavax CEO Expects Filing For Covid Vaccine Approval In December: Report
Novavax Inc expects filing for approval of its COVID-19 vaccine candidate in the United States in December, Chief Executive Stanley Erck said in an interview for Czech daily Hospodarske Noviny, released on Thursday.
-
US Firm Aims To Make 1 Billion COVID-19 Vaccine Doses After Buying Plant
Novavax Inc is buying a manufacturing plant from privately held Serum Institute of India, the world's largest maker of vaccines by volume, as the U.S. company aims to produce 1 billion doses of its COVID-19 vaccine candidate next year.
-
Novavax's Covid Vaccine Gets Emergency Use Nod For Kids Aged 12-17 In India
Novavax Inc said on Tuesday its COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years.
-
Japan Approves Moderna Covid Booster Shots Aiming To Increase Coverage
Japan on Thursday officially approved Moderna Inc's COVID-19 vaccine for its booster programme, while Novavax Inc filed for first approval of its shot in the country.
-
Novavax Covid Vaccine Gets First Authorization, "More Expected" Says CEO
Novavax Inc expects regulators in India, the Philippines and elsewhere to make a decision on its COVID-19 vaccine within "weeks," its CEO said after the shot received its first emergency use authorization (EUA) from Indonesia.
-
Novavax-Serum Institute Vaccine Gets Emergency Use Approval In Indonesia
Biotechnology firm Novavax Inc and its partner Serum Institute of India on Monday said they have received the first emergency use authorisation (EUA) for Novavax''s COVID-19 vaccine, in Indonesia.
-
Serum Institute Seeks India Trial Of A Second Covid Vaccine
The Serum Institute of India, the world's biggest vaccine makers, has sought the drug regulator's permission to conduct a small domestic trial of the Novavax Inc COVID-19 vaccine that was found to be 89.3% effective in a UK trial, its CEO told Reuters on Friday.
-
Novavax Delays US Trial Of COVID-19 Vaccine Candidate To November
Novavax Inc on Tuesday delayed the start of a late-stage US trial of its experimental coronavirus vaccine by roughly a month to the end of November, citing delays in scaling up the manufacturing process.
-
Novavax CEO Expects Filing For Covid Vaccine Approval In December: Report
Novavax Inc expects filing for approval of its COVID-19 vaccine candidate in the United States in December, Chief Executive Stanley Erck said in an interview for Czech daily Hospodarske Noviny, released on Thursday.
-
US Firm Aims To Make 1 Billion COVID-19 Vaccine Doses After Buying Plant
Novavax Inc is buying a manufacturing plant from privately held Serum Institute of India, the world's largest maker of vaccines by volume, as the U.S. company aims to produce 1 billion doses of its COVID-19 vaccine candidate next year.
